Ezabenlimab (Not yet branded)
Immunotherapy
Description
Ezabenlimab is a monoclonal antibody immunotherapy agent that targets the PD-1 (programmed death-1) receptor on T cells. This checkpoint inhibitor is being developed for treatment of advanced colorectal cancer, particularly in combination with other targeted agents. Based on clinical trial data, it shows activity in microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) colorectal tumors, as well as potential broader applications in combination therapy approaches.
Mechanism of Action
Ezabenlimab binds to the PD-1 receptor on activated T cells, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2. This blockade prevents tumor cells from suppressing the immune response, allowing T cells to maintain their anti-tumor activity and potentially leading to tumor regression.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.